Trimel Pharmaceuticals Corp. Company Profile (OTCMKTS:TRLPF)

About Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)

Trimel Pharmaceuticals Corp. logoTrimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, was approved for sale in the United States by the FDA in May 2014. It is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children. Trimel is also developing Tefina™, a use-as-required testosterone nasal gel for the treatment of female orgasmic disorder. Tefina™ has completed a number of clinical studies, including a large Phase II trial in April 2014, where the product positively showed statistical significance and was found to be well-tolerated. In July 2014, Trimel acquired the Canadian rights to Estrace® (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • CUSIP: N/A
  • Web:
  • Market Cap: $18.33 million
  • Outstanding Shares: 213,118,000
Average Prices:
  • 50 Day Moving Avg: $0.09
  • 200 Day Moving Avg: $0.09
  • 52 Week Range: $0.07 - $0.20
  • Trailing P/E Ratio: 8.600
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $15.35 million
  • Price / Sales: 1.19
  • Book Value: $0.05 per share
  • Price / Book: 1.72
  • EBIDTA: $5.28 million
  • Net Margins: 45.53%
  • Return on Equity: 24.59%
  • Return on Assets: 10.47%
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 1.97%
  • Quick Ratio: 1.14%
  • Average Volume: 21,606 shs.
  • Beta: 1.42

Frequently Asked Questions for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)

What is Trimel Pharmaceuticals Corp.'s stock symbol?

Trimel Pharmaceuticals Corp. trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Trimel Pharmaceuticals Corp.'s earnings last quarter?

Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) released its quarterly earnings results on Wednesday, March, 18th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.02. Trimel Pharmaceuticals Corp. had a net margin of 45.53% and a return on equity of 24.59%. View Trimel Pharmaceuticals Corp.'s Earnings History.

Who are some of Trimel Pharmaceuticals Corp.'s key competitors?

How do I buy Trimel Pharmaceuticals Corp. stock?

Shares of Trimel Pharmaceuticals Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trimel Pharmaceuticals Corp.'s stock price today?

One share of Trimel Pharmaceuticals Corp. stock can currently be purchased for approximately $0.09.

MarketBeat Community Rating for Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Trimel Pharmaceuticals Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
DateFirmActionRatingPrice TargetDetails
3/22/2017Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 6/29/2015 forward)


Earnings History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Earnings by Quarter for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Earnings History by Quarter for Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2015($0.01)($0.01)ViewN/AView Earnings Details
3/18/2015($0.02)($0.04)ViewN/AView Earnings Details
11/7/2014($0.02)($0.02)ViewN/AView Earnings Details
6/17/2014($0.04)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Current Year EPS Consensus Estimate: $-0.02 EPS


Dividend History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
No insider trades for this company have been tracked by


Headline Trends for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
Latest Headlines for Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF)
DateHeadline logoKaryopharm Reports Positive Multiple Myeloma Study Data - September 7 at 11:37 AM



Trimel Pharmaceuticals Corp. (TRLPF) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by Staff